Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Prothena Corp (NQ: PRTA )

24.43 -0.36 (-1.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 313,345
Open 25.09
Bid (Size) 24.51 (1)
Ask (Size) 26.50 (3)
Prev. Close 24.79
Today's Range 24.14 - 25.41
52wk Range 18.69 - 70.09
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
From Prothena Corporation plc
Via Business Wire

Performance

YTD
-36.61%
-36.61%
1 Month
+17.62%
+17.62%
3 Month
+18.82%
+18.82%
6 Month
-23.80%
-23.80%
1 Year
-60.79%
-60.79%

More News

Read More
PRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Demystifying Prothena Corp: Insights From 8 Analyst Reviews
Via Benzinga
Decoding 6 Analyst Evaluations For Prothena Corp
Via Benzinga
Prothena Corp: Q4 Earnings Insights
Via Benzinga
Prothena to Report First Quarter 2024 Financial Results on May 8
From Prothena Corporation plc
Via Business Wire
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
From Prothena Corporation plc
Via Business Wire
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
Earnings Scheduled For February 15, 2024
Via Benzinga
Earnings Outlook For Prothena Corp
Via Benzinga
Navigating 5 Analyst Ratings For Prothena Corp
Via Benzinga
$100 Invested In Prothena Corp 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
Prothena Appoints David Ford to Newly Created Chief People Officer Position
From Prothena Corporation plc
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
From Prothena Corporation plc
Via Business Wire
Demystifying Prothena Corp: Insights From 5 Analyst Reviews
Via Benzinga
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
From Prothena Corporation plc
Via Business Wire
Hewlett Packard Enterprise, Hologic And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.